Danaher stock: 3 ways Masimo acquisition could drive it much higher

Masimo (NASDAQ: MASI) pushed meaningfully higher on Feb. 17 after healthcare giant Danaher (NYSE: DHR) said it will acquire the pulse oximetry leader for $180 a share in cash.

Valued at about $9.9 billion, this agreement will see Masimo go private and become a “standalone” unit within Danaher’s diagnostics segment.

While MASI shareholders are enjoying an immediate payday, the real story for long-term investors lies in Danaher stock that remains down some 15% versus its year-to-date high.

By swallowing a high-growth medical innovator, DHR is positioning itself for a massive re-rating as it integrates Masimo’s “sticky” hospital technology into its legendary operational engine.

Why Masimo acquisition is bullish for Danaher stock

Investors cheered Masimo news on Tuesday mostly because the application of Danaher Business System (DBS) to its existing operations could unlock significant upside in DHR stock.

Historically, the NYSE-listed behemoth has excelled at taking “high-quality” technical companies and radically improving their margins through lean manufacturing and discipline execution.

Masimo currently operates with EBITDA margins notably below Danaher’s corporate average.

By streamlining its supply chain and administrative functions, DHR expects to see about $125 million in annual cost synergies.

According to analysts, this operational “tune-up” could boost Danaher’s adjusted EPS by some 70 cents within five years – providing a predictable tailwind for its valuation as profitability outpaces revenue growth.

DHR shares could benefit as MASI expands reach

Masimo's acquisition makes Danaher shares more attractive, also because it broadens the company’s reach from the laboratory to the hospital bedside.

Importantly, this buyout brings Signal Extraction Technology (SET) under DHR’s umbrella, which is currently the gold standard for non-invasive patient monitoring, used in the top ten US hospitals.

By folding MASI into its diagnostics segment – alongside powerhouses like Cepheid and Beckman Coulter – Danaher is effectively creating a comprehensive acute care ecosystem.

This will enable Danaher to cross-sell diagnostic tests and monitoring solutions, creating a unified platform for clinical decision-making.

In short, diving into hospital workflows may lead to more resilient, recurring revenue streams that insulate DHR from the cyclicality often seen in pure-play life sciences tools.

Masimo expands Danaher’s footprint in AI solutions

Beyond hardware, this deal gives Danaher a treasure trove of patient data and artificial intelligence (AI) enabled monitoring capabilities.

Masimo has spent years developing “algorithms” capable of predicting patient deterioration before it becomes critical.

Under DHR, which has bolstered its own digital and AI leadership, these tech will be scaled globally.  

The combination of Danaher’s global distribution and MASI’s advanced sensors will drive roughly $50 million in annual revenue synergies by year five.

All in all, as healthcare shifts toward data-driven outcomes, Danaher’s ability to sell “intelligent” diagnostic ecosystems may command a higher PE multiple, propelling DHR shares to new heights.